Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma
Rattachement africain : hk, cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Multiple myeloma (MM) bears heterogeneous cells that poses a challenge for single-target immunotherapies. Here we constructed bispecific CS1-BCMA CAR-T cells aiming to augment BCMA targeting with CS1. Sixteen patients with relapsed or refractory (RR) MM received CS1-BCMA CAR-T infusion. Six patients (38%) had cytokine release syndrome, which was of grade 1-2 in 31%. No neurological toxicities were observed. The most common severe adverse events were hematological, including leukopenia (100%), neutropenia (94%), lymphopenia (100%) and thrombocytopenia (31%). Three patients with solitary extramedullary disease (sEMD) did not respond. At a median follow-up of 246 days, 13 patients (81%) had an overall response and attained minimal residual disease-negativity, and six (38%) reached a stringent complete response (sCR). Among the 13 responders, 1-year overall survival and progression-free survival were 72.73% and 56.26%, respectively. Four patients maintained sCR with a median duration of 17 months. Four patients experienced BCMA+ and CS1+ relapse or progression. One patient responded after anti-BCMA CAR-T treatment failure. Lenalidomide maintenance after CAR-T infusion and the resistance mechanism of sEMD were preliminarily explored in three patients. CAR-T cells persisted at a median of 406 days. Soluble BCMA could serve as an ideal biomarker for efficacy monitoring. CS1-BCMA CAR-T cells were clinically active with good safety profiles in patients with RRMM. Clinical trial registration: This study was registered on ClinicalTrials.gov, number NCT04662099.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma
- Date Crossref
- 17/10/2023
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Union Hospital pays non établi dans la noticeÉtablissement de santé
-
Hubei Cancer Hospital pays non établi dans la noticeÉtablissement de santé
-
Huazhong University of Science and Technology pays non établi dans la noticeUniversité ou école supérieure
-
Wuhan Union Hospital pays non établi dans la noticeÉtablissement de santé
-
Shanghai Cell Therapy Research Institute pays non établi dans la noticeOrganisation à but non lucratif
-
Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease pays non établi dans la noticeÉtablissement de santé
-
Tongji Medical College Institute of Hematology pays non établi dans la noticeUniversité ou école supérieure
-
Ltd Wuhan Wuhan Sian Medical Technology Co. pays non établi dans la noticeEntreprise
Union Hospital, Hubei Cancer Hospital et Huazhong University of Science and Technology, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.